As of today (2024-05-03), Biofrontera's share price is $1.72. Biofrontera's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.43. Hence, Biofrontera's Price to Tangible Book Ratio of today is 1.21.
The historical rank and industry rank for Biofrontera's Price-to-Tangible-Book or its related term are showing as below:
BFRI'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.17 Med: 1.94 Max: 16.31
Current: 1.2
During the past 5 years, Biofrontera's highest Price to Tangible Book Ratio was 16.31. The lowest was 1.17. And the median was 1.94.
BFRI's Price-to-Tangible-Book is ranked better than 77.89% of 873
companies
in the Drug Manufacturers industry
Industry Median: 2.34
vs BFRI: 1.20
Biofrontera Price-to-Tangible-Book Historical Data
The historical data trend for Biofrontera's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biofrontera's Price-to-Tangible-Book
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Biofrontera's Price-to-Tangible-Book falls into.
Biofrontera Price-to-Tangible-Book Calculation
Biofrontera's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Biofrontera Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Biofrontera's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BFRI has been successfully added to your 